Document:

Offer Letter, by and between Amar Singh and Novacea, Inc.

 EXHIBIT 10.17 
  

					
	 	 	Novel Therapies Improving Lives        	  	 601 Gateway Blvd., Suite 800
 South San Francisco, CA 94080

	 	 	 	  	t: 650 228 1800
	 	 	 	  	 f: 650 228 1088
 www.novacea.com

  
 

 
  
 January 27, 2006 
  
 Amar Singh

  
 Dear Amar: 
  
 I am pleased to offer you, the position of Chief Commercialization Officer for Novacea
effective February 28, 2006, reporting to Brad Goodwin, Chief Executive Officer. As we are a dynamic organization, you may also be involved in matters other than commercialization to which you can lend your expertise. 
  
 Your base compensation will be $12,083.34 per pay period (semi-monthly) which equates to
$290,000.00 annualized. Your annual bonus opportunity will be up to 30% of your earned base compensation based upon company performance and individual performance objectives to be agreed upon mutually. In addition, you will be paid a one-time
sign-on bonus of $60,000.00 payable after thirty days of employment. One half of your sign on bonus will be repayable to Novacea if you voluntarily leave the Company within two years of your date of hire; one quarter will be repayable to Novacea if
you voluntarily leave the Company within three years of your date of hire. 
  
 Novacea will reimburse you for the following relocation assistance: any reasonable moving costs up to a maximum of $15,000.00; and the closing costs associated with the sale of your current residence in Southern California up to a maximum
of $60,000.00. These costs are only reimbursable upon filing an expense report with all original receipts for moving expenses, and documentation proving the sale of your residence. One half of all above relocation assistance will be repayable to
Novacea if you voluntarily leave the Company within two years of your date of hire; one quarter will be repayable to Novacea if you voluntarily leave the Company within three years of your date of hire. 
  
 Subject to the approval of the Board of Directors at their first meeting after your
employment commences with us, you will be issued an option to purchase 700,000 shares of the Common Stock of the Company priced at the fair market value of our stock on the date of grant with vesting over four years: 25% at the end of 12 months and
then monthly thereafter. A copy of the Incentive Stock Option Agreement and the Company’s standard form of Optionee Restriction Agreement will be provided after approval by the Board. 
  
 Effective with your hire date, you will be eligible to earn twenty-one (21) Paid Time
Off or PTO days, accruing every pay period and subject to a maximum balance of 37 days, as well as all company paid holidays. We are enclosing a copy of the 2006 Your Benefits overview. Please note that fringe benefits established by the
Company, which currently include medical, dental, vision, life/AD&D and disability benefits, start on the first of the month following your date of hire. Eligibility for the 401(k) plan starts the first day of the following quarter after
completing 30 days of employment. You should confirm the end date of health coverage from your prior employer by providing us your Certificate of Health Coverage. 

 Novacea will reimburse you for all reasonable and necessary out-of-pocket expenses incurred by you in connection with
services rendered on behalf of Novacea, subject to you providing appropriate substantiation in accordance with Company policy. 
  
 Under immigration law, we are required to verify each new employee’s identity and legal authority to work in the United States. Accordingly, please be prepared to
furnish appropriate documents satisfying those requirements no later than 72 hours of your start date. This offer of employment is conditioned upon satisfactory documentation. 
  
 This letter, the attached Patent, Copyright and Non-Disclosure Agreement, and such other agreements as set forth in the Employee
Handbook, constitute all agreements with respect to your employment. However, Novacea may, in its sole discretion, adjust the compensation and benefits paid to you and its other employees. 
  
 Your employment is at will, which means that either you or the Company may terminate your
employment at any time, with or without cause for any reason or no reason whatsoever. This employment at-will provision cannot be waived by Novacea unless done in writing by our CEO. 
  
 Amar, we look forward to your significant contributions in this critical role, as we move forward revolutionizing the way we treat cancer,
along with the opportunity to create a successful “world class” development and commercialization organization. If you accept this offer, please sign and return a copy with the above referenced attachments to Barbara Kehoe (fax number:
650-228-1084). 
  
 Sincerely, 
  

	
	 /s/ Bradford S. Goodwin

	Bradford S. Goodwin
	Chief Executive Officer

  
 cc: Human Resources 
  
 Attachment: 
     Patent, Copyright and Non-Disclosure Agreement 
  

											
	 Accepted:
	 	 /s/    Amar Singh        

	 	 	 	Date:	 	  

	 	 
	 	 	Amar SinghLetter Amendment

 EXHIBIT 10.24 
  

					
	 	 	Novel Therapies Improving Lives        	  	 601 Gateway Blvd., Suite 800 South
 San Francisco, CA 94080

	 	 	 	  	t: 650 228 1800
	 	 	 	  	 f: 650 228 1088
 www.novacea.com

  
 

 
  
 Confidential 
  
 November 21, 2005 
  
 Mr. Arundeep S. Pradhan 
 Director of Technology Research 
 Collaborations Oregon Health Sciences 
 University 
 Mail code: AD 120 
 2525 SW First Avenue, Suite 120 
 Portland, OR 97201 
  
 Re: Amendment to June 21, 2001 Agreement (OHSU Tech ID 413 License Amendment) 
  
 Dear Arun: 
  
 In going back through our files I realized that we have yet to finalize the changes to the
June 27, 2001 Exclusive License Agreement (the “Agreement”) that have been discussed with your office over the course of the past year. More specifically: 
  
 Articles 1 and 3: As you know, [*] the Agreement lacks a definition of “Knowhow” and there is no express license to Novacea
covering this unpatented data. As a result, we’ve proposed that “Licensed Knowhow” shall be included in the Article 2 Definitions and be defined as: 
  
 2.12 
 “...all proprietary information, methods, processes, techniques, data and biologic materials (including, without limitation, pre-clinical and clinical data) which are in the possession of or controlled by OHSU during the term of this

 
Agreement, which OHSU is free to license or sublicense, and which is necessary or useful for the manufacture, use or sale of a Licensed Product in the Field
or to practice any Licensed Process in the Field in the Licensed Territory. Except as otherwise expressly agreed by the parties, the license to Novacea of Licensed Knowhow set forth above shall not obligate OHSU to conduct additional research or
otherwise initiate any action with respect to the creation of new Licensed Knowhow. 
  
 We would then revise Section 3.01 to add “and Licensed Knowhow” after the words “Licensed Patent Rights” in line three. We would also revise Section 3.04 to add “and Licensed Knowhow” after
“Licensed Patent Rights” in lines three and four. 
  
 Section 5.01: Add “Licensed Knowhow” after the words “Licensed Patent Rights” in line three. 
  
 Section 5.02: While this clause may be appropriate in a license covering a proprietary composition of matter, it is problematic with respect to a method patent - as
DN-101 lacks composition of matter coverage and can lawfully be manufactured anywhere. We would like to delete this. 
  
 Section 6.02(b): Pursuant to my discussions with Jessica Zeaske and Mary Foley, we have proposed that this sub-section be written as follows: 
  
 “In the event that any Licensed Product or practice of Licensed Process incorporates
other patent rights or rights in other intellectual property for which royalties are due by Licensee, then Licensee shall not be required to stack its royalty payments, and [*] percent ([*]%) of such royalties may be offset against earned royalties
due to OHSU, provided that the amount to be paid under the paragraph 6.02(a) shall not be less than [*] percent ([*]%) of Net Sales of the Licensed Products or Licensed Processes.” 
  
 Sections 11.02-11.04: Add reference to “or interference proceedings” following the references to “infringement action”
to assure that Novacea’s rights and responsibilities extend to such proceedings. 
  
 Appendix A: Updated to reflect current status. 
  

If the foregoing if acceptable to you, please countersign the attached duplicate original of this letter and return it my attention. If you have any questions, please
feel free to give me a call. 
  
 Regards,

  

	
	 /s/ Brad Goodwin

	 Brad Goodwin

	 CEO

  

 [*] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 Agreed this        day of November, 2005

  

	
	 /s/ Arundeep S. Pradhan

  
 OREGON HEALTH AND SCIENCE UNIVERSITY 
  

	By:	Arundeep Pradhan 

  

	Its:	Director, Technology & Research Collaborations 

  
 CC: Paul Westberg (Novacea); Ed Albini (Novacea); Mary Foley, PhD (OHSU) 

			
	OHSU Tech ID 413 License Amendment	  	11/8/2005

  
 Appendix A 
  
 Patent Status for Technology Disclosure
413, “Pulse Doses of Vitamin D and Analogues as Anticancer Therapy”—as of 11/8/2005 
  

													
	 Patent Appl
 Type

	  	 Country

	  	 File Dat

	  	 Serial No.

	  	 Patent No

	  	 Patent Status

	  	 Legal Ref.

	[*]	  	[*]	  	[*]	  	[*]	  	[*]	  	[*]	  	[*]
	[*]	  	[*]	  	[*]	  	[*]	  	[*]	  	[*]	  	[*]
	[*]	  	[*]	  	[*]	  	[*]	  	[*]	  	[*]	  	[*]
	[*]	  	[*]	  	[*]	  	[*]	  	[*]	  	[*]	  	[*]
	[*]	  	[*]	  	[*]	  	[*]	  	[*]	  	[*]	  	[*]
	[*]	  	[*]	  	[*]	  	[*]	  	[*]	  	[*]	  	[*]
	[*]	  	[*]	  	[*]	  	[*]	  	[*]	  	[*]	  	[*]
	[*]	  	[*]	  	[*]	  	[*]	  	[*]	  	[*]	  	[*]
	[*]	  	[*]	  	[*]	  	[*]	  	[*]	  	[*]	  	[*]

  

 [*] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00100-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00100-of-00352.parquet"}]]